Humanized antibodies against monocyte chemotactric proteins
AssigneeBiogen Idec MA Inc.
InventorsAntonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
Life of this patent
Estimating the term…
Abstract
The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
Claims46
A humanized immunoglobulin or antigen-binding fragment thereof comprising a) heavy chain complementarity determining regions as set forth in SEQ ID NO:29, SEQ ID NO:30, and SEQ ID NO:31, and b) light chain complementarity determining regions as set forth in SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34.
A humanized immunoglobulin or antigen-binding fragment comprising a) heavy chain complementary determining regions as set forth in SEQ ID NO:
- 29, SEQ ID NO:
- 30, and SEQ ID NO:
- 31, and variable region framework residues L27, N28, I29, K30, I48, A67, and T73 (Kabat numbering) from the monoclonal antibody 11K2 heavy chain set forth as SEQ ID NO:
- 27, and b) light chain complementary determining regions as set forth in SEQ ID NO:
- 32, SEQ ID NO:
- 33, and SEQ ID NO:
- 34, and variable region framework residues S49, K69, and Y71 (Kabat numbering) from the monoclonal antibody 11K2 light chain set forth as SEQ ID NO:
- 28, wherein the remainder of the heavy and light chains are from a human immunoglobulin.
An antibody comprising the same heavy and light chain polypeptide sequences as an antibody produced by clone 3F2 (ATCC patent deposit designation PTA-5308).
Dependencies are inferred from the claim text.